Plus Therapeutics Stock Soars 33.69% on Restructuring Announcement

Plus Therapeutics' stock surged 33.69% in pre-market trading on June 25, 2025, driven by significant corporate restructuring announcements.

Plus Therapeutics has announced a comprehensive restructuring of its previous $15 million equity financing, initially disclosed on March 4, 2025. This strategic move aims to eliminate potential dilution of up to 1.5 billion shares of common stock, thereby enhancing shareholder value. The restructuring involves the cancellation of warrants associated with the equity financing, which could have resulted in the issuance of up to 1.51 billion shares of common stock. This action leaves approximately 36 million shares of common stock issuable upon exercise of amended Series B Warrants at an alternative cashless exercise ratio of 1:1. Additionally, the restructuring will lead to the cancellation of approximately 25 million shares of common stock, further reducing stockholder dilution.

The company has also filed a request with the U.S. Securities and Exchange Commission to withdraw the resale registration statement related to the March 2025 Equity Financing. This move is part of a broader strategy to streamline the capital structure and protect shareholder value. Plus Therapeutics plans to use 90% of future proceeds from any capital raised subsequent to July 1, 2025, to repay the holders of 22,727,270 shares of common stock at 115%. This restructuring is expected to have a positive impact on the company's financial health and market perception, contributing to the significant pre-market stock price increase.